Abstract
Myxovirus resistance protein A (MxA) belongs to dynamin superfamily. MxA is a component of antiviral response and is solely induced by interferons, thus by in vivo application of interferon β (INFβ) as well.
In patients with multiple sclerosis (MS), neutralizing antibodies (NAbs) appearing during INFβ treatment in 10-30 % of cases, decrease its bioactivity and therapeutic efficacy. The aim of this study was to show the correlation of MxA and Nabs levels on the cohort with relaps-remitting form of MS (RR-MS) and to set up the cutoff value for the baseline levels of MxA in population.
The cohort sustained of 16 NAbs positive, 43 NAbs negative patients and 105 negative controls. This study demonstrates high correlation in high NAbs levels and depletion of MxA expression.
The cutoff MxA/GAPDH (baseline) value was assigned as a 95 percentile of values of negative controls: MxA/GAPDH = 160.